Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | The role of radiotherapy in bladder preservation for patients with muscle-invasive bladder cancer

Robert Huddart • 22 Oct 2023
ESMO 2023
Bladder Cancer Genitourinary Cancer Urothelial Carcinoma
RADAR

Robert A. Huddart, PhD, FRCR, MRCP, MBBS, The Institute of Cancer Research, London, UK, discusses the role of radiotherapy in bladder preservation for patients with muscle-invasive bladder cancer, delving into the patient requirements that would make them eligible for radical cystectomy evasion. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Robert Huddart

The role of immunotherapy after radiation in bladder cancer
1:11
The role of immunotherapy after radiation in bladder cancer
Robert Huddart • 13 Feb 2025
RE-ARM: radiotherapy as an immune-priming strategy in bladder cancer
1:46
RE-ARM: radiotherapy as an immune-priming strategy in bladder cancer
Robert Huddart • 13 Feb 2025
PLUMMB: final results of pembrolizumab & hypofractionated RT in bladder cancer
2:29
PLUMMB: final results of pembrolizumab & hypofractionated RT in bladder cancer
Robert Huddart • 13 Feb 2025
The role of erdafitinib in treating patients with bladder cancer
2:20
The role of erdafitinib in treating patients with bladder cancer
Robert Huddart • 22 Oct 2023

Related Videos

Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
1:55
Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
Sarah Howlett • 26 Oct 2026
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
2:20
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
Jens Bedke • 26 Oct 2026
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
2:24
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
Jens Bedke • 26 Oct 2026
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
2:58
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
Jens Bedke • 26 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals